Solifenacin
Summary
Persistence. It cannot be excluded that solifenacin is persistent, due to the lack of data.
Bioaccumulation. Solifenacin has low potential for bioaccumulation.
Toxicity. It cannot be excluded that solifenacin is toxic, due to the lack of data.
Risk. Both ecotoxicological effect data and environmental measurements are limited for incontinence pharmaceuticals. However, excretion data, available ecotoxicological effect data, and risk assessment using the fish plasma model for both parent compounds and active metabolites consistently indicate a negligible environmental risk associated with the use of the three anticholinergic substances solifenacin, tolterodine, and fesoterodine from a Swedish perspective. For mirabegron, which is considered persistent in the environment, the risk is somewhat higher but still low. Therefore, no substitutions are recommended from an environmental risk perspective.
This summary information comes from fass.se. The risk assessment is taken from the Goodpoint 2026 review.
Detailed information
Fass environmental information
Fass environmental information for Vesicare (solifenacin) from Astellas Pharma AB (retrieved on 2026-01-16).
Hazard
Persistence: No data.
Bioaccumulation: The Log P of solifenacin succinate is 3.67650, indicating a low potential for bioaccumulation. This supports the use of the standard phrase: "Solifenacin succinate has low potential for bioaccumulation."
Toxicity: No data.
Risk
PEC/PNEC is based on sales data in Sweden in year 2023.
PEC = 0.0048 microg/L.
The risk of environmental impact from solifenacin cannot be excluded due to the lack of ecotoxicological data.
Environmental assessment by Goodpoint 2026
Both ecotoxicological effect data and environmental measurements are limited for incontinence pharmaceuticals. However, excretion data, available ecotoxicological effect data, and risk assessment using the fish plasma model for both parent compounds and active metabolites consistently indicate a negligible environmental risk associated with the use of the three anticholinergic substances solifenacin, tolterodine, and fesoterodine from a Swedish perspective. For mirabegron, which is considered persistent in the environment, the risk is somewhat higher but still low. Therefore, no substitutions are recommended from an environmental risk perspective.
Author: Health and Medical Care Administration, Region Stockholm